Capital & Investment Signal Shows Only 31.8% of 673 Monetary Figures Are Transactions as Two Deals Make Up 47.4% of $52.35 Billion in Aggregable Capital

InnoDexis has published its latest Innovation Intelligence Report covering capital and investment signal, analyzing 673 monetary figures in 487 of 4,840 corporate records, including 123 funding rounds and 247 acquisitions, during the 1–29 September 2026 observation window. The report reveals that two-thirds of the money in innovation news is not money changing hands: only 214 figures, 31.8 percent, are aggregable transactions worth $52.35 billion, and records carrying a transaction show High market momentum 34.8 percent of the time against 10.8 percent.

Key Findings

Most figures are not transactions. Of 673 monetary figures, 214, 31.8 percent, are aggregable transactions worth $52.35 billion, while capital-investment plans total $228.5 billion across 119 figures, valuations $59.5 billion, programme ceilings and milestones $30.5 billion and debt $17.2 billion, so a reader who sums headline numbers would overstate transactions several times over.

Acquisitions dominate value. They account for $44.92 billion in 35 figures, and two deals, Shell–ARC Resources at $13.9 billion and AbbVie–Apogee at $10.9 billion, are 47.4 percent of all aggregable capital, while the top five deals make up 68.3 percent.

Venture is broad and shallow. The 132 private rounds total $4.52 billion at a median of $8.6 million, and six reached $100 million or more: Stoke Space at $1 billion, XPeng’s robotics round over $900 million, Snorkel AI at $350 million, Basecamp Research at $140 million, Thyme Care at $125 million and HiddenLayer at $100 million.

Stage predicts momentum. High momentum rises from 10.4 percent at grants to 32.0 percent at seed, 64.3 percent at Series A, 81.8 percent at Series B and 80.0 percent at Series C, and funding-round announcements score 6.34 with 44.7 percent High momentum, the highest of any common announcement type.

Public money is a fifth of funding and capital follows physical technology. The 29 public grants and programmes total $1.69 billion, while energy holds $16.01 billion of aggregable value and therapeutics $11.26 billion, and AI and software leads by count with 53 figures.

Strategic Insight and Trend Analysis

The defining structural finding is that figures are not funds. Plans, ceilings, valuations and debt outnumber transactions two to one by count and many times by value, so curation is the analytical step that makes capital data usable. Where capital does change hands it marks momentum, with records carrying an aggregable transaction showing High momentum 34.8 percent of the time against 10.8 percent for the rest. Debt, at 15.2 percent, and IPOs, at 25.0 percent, sit below equity growth stages.

Capital is concentrated at the top and thin beneath it. Two deals are 47.4 percent of aggregable value, so monthly totals are dominated by individual transactions, while the 132 private rounds are spread from 20 at $1 million or less to 6 at $100 million or more. Large rounds go to robotics, AI data and models, AI-designed therapeutics, care navigation and AI security.

Option-style and public money sit beside the transactions. Seventy-one programme ceilings worth $30.5 billion, including Kimberly-Clark, Nscale with Figure, Alteogen with Novartis and Hengrui with Novo Nordisk, are potential rather than paid, and public programmes such as the Henry Royce and Rosalind Franklin Institutes at £160 million invite private co-investment. Figures are parsed from text and converted at fixed indicative rates, classification is rule-based, stage samples are small above Series A and one month supports no trend.

Global and Industry Implications

For corporates and R&D teams, acquirers in energy, pharma and aerospace are buying capacity, assets and data, and tuck-ins in AI and services dominate counts. Energy and therapeutics hold $27.3 billion of aggregable value. Option-style licences for clinical assets carry ceilings rather than cash, so Series B and later rounds are the acquisition pipeline to track.

For investors and capital allocators, classify every figure before summing and treat stage as the momentum signal, favouring Series A to C rounds, which carry 64 to 82 percent High momentum. Named opportunities include mid-stage AI security, such as HiddenLayer, AIR and Baselayer, AI data at Snorkel AI, AI-designed therapeutics at Basecamp Research and robotics at XPeng, and due diligence should separate ceilings and valuations from cash.

For policymakers and national innovation bodies, public programmes anchor private co-investment, as the City of Hamilton housing funding, the MBTA transport programme and the Henry Royce Institute materials programme show, and publishing co-investment terms is the named priority. Public money is a fifth of disclosed funding, with 29 programmes worth $1.69 billion.

InnoDexis Statement

“Two-thirds of the money in innovation news is not money changing hands — the useful signal is a real round at a named stage, not the size of a headline number,” noted InnoDexis in its latest intelligence report.

Conclusion

Because figures are parsed from text and converted at fixed indicative rates, classification is rule-based, stage samples are small above Series A and one month supports no trend, the findings are cross-sectional. The signals to watch are whether the top two deals’ share stays above 40 percent, whether private rounds of $100 million or more appear outside AI and robotics, whether the debt share rises, and whether a public programme names private co-investors. Each is a specific, observable test. The complete Capital & Investment Signal Report September 2026 is available to InnoDexis subscribers and enterprise clients.

About InnoDexis

InnoDexis is a real-time innovation intelligence platform connecting scientific discovery to commercial opportunity. Powered by InnoGraph, its proprietary innovation knowledge graph, the platform maps technologies across the entire lifecycle, from early-stage research (TRL 1) to market deployment (TRL 9), connecting researchers, institutions, startups, companies, products and emerging opportunities.

Covering 40+ specialised industry segments and 360 technology areas, InnoDexis delivers innovation tracking, research discovery, product and startup intelligence, investment insights, and AI-powered reports. Its mission is to bridge the gap between scientific discovery and real-world impact.

InnoDexis — From Lab to Market: Real-Time Innovation Intelligence.